Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcus Biosciences, Inc.RCUS · Entity 4104 | Director | January 29, 2024 | February 07, 2024 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Comm & Corp Aff Officer | September 15, 2026 | September 16, 2026 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcus Biosciences, Inc.
Report date January 29, 2024 · Filed February 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2024-01-29 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
GILEAD SCIENCES, INC.
Report date September 15, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,684 |
Ending reported balance
After 2026-09-15 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-15 · Sale · Disposed 1,600 · Balance 118,084 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F2: Sale prices for the transactions reported range from $143.16 to $144.15. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Row 2 · 2026-09-15 · Sale · Disposed 800 · Balance 117,284 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F3: Sale prices for the transactions reported range from $144.26 to $144.775. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Row 3 · 2026-09-15 · Sale · Disposed 600 · Balance 116,684 F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.
F2: Sale prices for the transactions reported range from $143.16 to $144.15. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F3: Sale prices for the transactions reported range from $144.26 to $144.775. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
NEUROCRINE BIOSCIENCES INC
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restriced Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,567 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 2,567 · Balance 2,567 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2: The RSUs will vest in full on May 27, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
F2: The RSUs will vest in full on May 27, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 16, 2026 20:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 600 | $145.29 | $87,174.00 |
DisclosureSEC source: 0001782135-26-000033 · wk-form4_1789590469.xml · nonDerivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,684 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 800 | $144.46 | $115,565.52 |
DisclosureSEC source: 0001782135-26-000033 · wk-form4_1789590469.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,284 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F3 · price: Sale prices for the transactions reported range from $144.26 to $144.775. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| September 15, 2026 Filed Sep 16, 2026 20:27 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,600 | $143.69 | $229,906.72 |
DisclosureSEC source: 0001782135-26-000033 · wk-form4_1789590469.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,084 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F2 · price: Sale prices for the transactions reported range from $143.16 to $144.15. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001782135-26-000031 · wk-form4_1789165734.xml · derivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,054 Underlying: Common Stock · 2,797 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,347 | $144.81 | $195,059.07 |
DisclosureSEC source: 0001782135-26-000031 · wk-form4_1789165734.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,684 Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001782135-26-000031 · wk-form4_1789165734.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 1,890 | $0.00 Strike: $72.34 | $0.00 |
DisclosureSEC source: 0001782135-26-000028 · wk-form4_1787093640.xml · derivative · entry 6 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,960 Underlying: Common Stock · 1,890 shares Expires 2030-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F4 · derivative.exercise_date: The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 23,110 | $0.00 Strike: $66.64 | $0.00 |
DisclosureSEC source: 0001782135-26-000028 · wk-form4_1787093640.xml · derivative · entry 5 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,110 shares Expires 2029-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F4 · derivative.exercise_date: The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 11,470 | $138.04 | $1,583,264.89 |
DisclosureSEC source: 0001782135-26-000028 · wk-form4_1787093640.xml · nonDerivative · entry 4 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,234 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F3 · price: Sale prices for the transactions reported range from $137.75 to $138.36. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 16,530 | $137.37 | $2,270,643.45 |
DisclosureSEC source: 0001782135-26-000028 · wk-form4_1787093640.xml · nonDerivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,704 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F2 · price: Sale prices for the transactions reported range from $136.74 to $137.73. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,890 | $72.34 | $136,722.60 |
DisclosureSEC source: 0001782135-26-000028 · wk-form4_1787093640.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. Read SEC document |
| August 17, 2026 Filed Aug 18, 2026 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 23,110 | $66.64 | $1,540,050.40 |
DisclosureSEC source: 0001782135-26-000028 · wk-form4_1787093640.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 144,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. Read SEC document |
| July 15, 2026 Filed Jul 16, 2026 20:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,000 | $129.92 | $389,757.60 |
DisclosureSEC source: 0001782135-26-000026 · wk-form4_1784235279.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,234 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F2 · price: Sale prices for the transactions reported range from $129.45 to $130.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 22:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 450 | $125.40 | $56,430.00 |
DisclosureSEC source: 0001782135-26-000024 · wk-form4_1781647325.xml · nonDerivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,234 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 22:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,070 | $124.00 | $132,675.51 |
DisclosureSEC source: 0001782135-26-000024 · wk-form4_1781647325.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,684 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F3 · price: Sale prices for the transactions reported range from $123.81 to $124.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 22:02 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,480 | $123.42 | $182,656.57 |
DisclosureSEC source: 0001782135-26-000024 · wk-form4_1781647325.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,754 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F2 · price: Sale prices for the transactions reported range from $122.79 to $123.785. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 22:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,796 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001782135-26-000022 · wk-form4_1781217068.xml · derivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,851 Underlying: Common Stock · 2,796 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 22:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,341 | $121.48 | $162,904.68 |
DisclosureSEC source: 0001782135-26-000022 · wk-form4_1781217068.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,234 Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 22:31 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,796 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001782135-26-000022 · wk-form4_1781217068.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| May 27, 2026 Filed May 29, 2026 22:04 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantRestriced Stock Unit · Derivative | 2,567 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001782135-26-000020 · wk-form4_1780092260.xml · derivative · entry 1 Mercier Johanna · CIK 0001782135 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,567 Underlying: Common Stock · 2,567 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: The RSUs will vest in full on May 27, 2027. F2 · derivative.expiration_date: The RSUs will vest in full on May 27, 2027. Read SEC document |
| May 21, 2026 Filed May 21, 2026 23:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionRestricted Stock Unit · Derivative | 3,318 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001782135-26-000018 · wk-form4_1779405685.xml · derivative · entry 2 Mercier Johanna · CIK 0001782135 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,318 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested. F2 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested. Read SEC document |
| May 21, 2026 Filed May 21, 2026 23:21 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 3,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001782135-26-000018 · wk-form4_1779405685.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2026 Filed May 18, 2026 21:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $66.64 | $0.00 |
DisclosureSEC source: 0001782135-26-000016 · wk-form4_1779140737.xml · derivative · entry 6 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,110 Underlying: Common Stock · 25,000 shares Expires 2029-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F6 · derivative.exercise_date: The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| May 15, 2026 Filed May 18, 2026 21:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 700 | $132.75 | $92,925.98 |
DisclosureSEC source: 0001782135-26-000016 · wk-form4_1779140737.xml · nonDerivative · entry 5 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,779 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F5 · price: Sale prices for the transactions reported range from $132.74 to $132.78. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| May 15, 2026 Filed May 18, 2026 21:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 8,374 | $132.23 | $1,107,314.12 |
DisclosureSEC source: 0001782135-26-000016 · wk-form4_1779140737.xml · nonDerivative · entry 4 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,479 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F4 · price: Sale prices for the transactions reported range from $131.71 to $132.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| May 15, 2026 Filed May 18, 2026 21:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 11,177 | $131.19 | $1,466,329.63 |
DisclosureSEC source: 0001782135-26-000016 · wk-form4_1779140737.xml · nonDerivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,853 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F3 · price: Sale prices for the transactions reported range from $130.67 to $131.505. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| May 15, 2026 Filed May 18, 2026 21:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 7,749 | $130.29 | $1,009,628.83 |
DisclosureSEC source: 0001782135-26-000016 · wk-form4_1779140737.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,030 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F2 · price: Sale prices for the transactions reported range from $129.66 to $130.63. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| May 15, 2026 Filed May 18, 2026 21:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 25,000 | $66.64 | $1,666,000.00 |
DisclosureSEC source: 0001782135-26-000016 · wk-form4_1779140737.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 22:40 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,000 | $140.96 | $422,880.00 |
DisclosureSEC source: 0001782135-26-000014 · wk-form4_1776379208.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,779 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 22:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,000 | $144.23 | $432,690.00 |
DisclosureSEC source: 0001782135-26-000012 · wk-form4_1773788187.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,779 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 35,880 | $0.00 Strike: $148.56 | $0.00 |
DisclosureSEC source: 0001782135-26-000010 · wk-form4_1773348121.xml · derivative · entry 5 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,880 Underlying: Common Stock · 35,880 shares Expires 2036-03-10 F3 · derivative.exercise_date: The stock options have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 9,590 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001782135-26-000010 · wk-form4_1773348121.xml · derivative · entry 4 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,647 Underlying: Common Stock · 9,590 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 6,617 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001782135-26-000010 · wk-form4_1773348121.xml · derivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,057 Underlying: Common Stock · 6,617 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 3,216 | $148.56 | $477,768.96 |
DisclosureSEC source: 0001782135-26-000010 · wk-form4_1773348121.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,779 Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:42 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 6,617 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001782135-26-000010 · wk-form4_1773348121.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 21:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 11,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001782135-26-000008 · wk-form4_1772488451.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,378 F1 · kind: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2025. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 22:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $66.64 | $0.00 |
DisclosureSEC source: 0001782135-26-000006 · wk-form4_1771453372.xml · derivative · entry 5 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,110 Underlying: Common Stock · 25,000 shares Expires 2029-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F4 · derivative.exercise_date: The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 22:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $155.62 | $31,124.00 |
DisclosureSEC source: 0001782135-26-000006 · wk-form4_1771453372.xml · nonDerivative · entry 4 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,288 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 22:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 9,395 | $154.91 | $1,455,384.15 |
DisclosureSEC source: 0001782135-26-000006 · wk-form4_1771453372.xml · nonDerivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,488 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F3 · price: Sale prices for the transactions reported range from $154.57 to $155.27 Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 22:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 18,405 | $154.18 | $2,837,719.71 |
DisclosureSEC source: 0001782135-26-000006 · wk-form4_1771453372.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,883 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F2 · price: Sale prices for the transactions reported range from $153.565 to $154.56 Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 22:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 25,000 | $66.64 | $1,666,000.00 |
DisclosureSEC source: 0001782135-26-000006 · wk-form4_1771453372.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 148,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 23:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 24,800 | $143.28 | $3,553,344.00 |
DisclosureSEC source: 0001782135-26-000004 · wk-form4_1770335486.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,288 Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 23:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 44,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001782135-26-000004 · wk-form4_1770335486.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Comm & Corp Aff Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,088 F1 · shares: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2023 and March 10, 2024. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. However, the shares certified for grants made March 10, 2024 will not be issued to the Reporting Person until the requisite continuing service requirements are also met. Read SEC document |
| January 15, 2026 Filed Jan 16, 2026 23:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,000 | $124.31 | $372,930.00 |
DisclosureSEC source: 0001782135-26-000002 · wk-form4_1768605033.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,221 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. Read SEC document |
| December 15, 2025 Filed Dec 16, 2025 23:12 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,000 | $122.00 | $366,000.00 |
DisclosureSEC source: 0001782135-25-000017 · wk-form4_1765926757.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,221 F1 · kind: The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 23:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 3,842 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001782135-25-000015 · wk-form4_1765495531.xml · derivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,674 Underlying: Common Stock · 3,842 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 23:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,814 | $121.34 | $220,110.76 |
DisclosureSEC source: 0001782135-25-000015 · wk-form4_1765495531.xml · nonDerivative · entry 2 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,221 Read SEC document |
| December 10, 2025 Filed Dec 11, 2025 23:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,842 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001782135-25-000015 · wk-form4_1765495531.xml · nonDerivative · entry 1 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 23:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $66.64 | $0.00 |
DisclosureSEC source: 0001782135-25-000013 · wk-form4_1763509908.xml · derivative · entry 4 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,110 Underlying: Common Stock · 25,000 shares Expires 2029-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F4 · derivative.exercise_date: The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 17, 2025 Filed Nov 18, 2025 23:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,476 | $126.26 | $312,613.57 |
DisclosureSEC source: 0001782135-25-000013 · wk-form4_1763509908.xml · nonDerivative · entry 3 Mercier Johanna · CIK 0001782135 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,193 F1 · kind: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025. F3 · price: Sales prices for the transactions reported here range from $126.23 to $126.39. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.